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Small cell lung carcinoma (SCLC) is a high-grade pul-
monary neuroendocrine tumor. The transcription
factors ASCL1 and NEUROD1 play crucial roles in
promoting malignant behavior and survival of human
SCLC cell lines. Here, we find that ASCL1 and
NEUROD1 identify heterogeneity in SCLC, bind
distinct genomic loci, and regulate mostly distinct
genes. ASCL1, but not NEUROD1, is present in
mouse pulmonary neuroendocrine cells, and only
ASCL1 is required in vivo for tumor formation in
mouse models of SCLC. ASCL1 targets oncogenic
genes including MYCL1, RET, SOX2, and NFIB while
NEUROD1 targets MYC. ASCL1 and NEUROD1 re-
gulate different genes that commonly contribute to
neuronal function. ASCL1 also regulates multiple
genes in the NOTCH pathway including DLL3.
Together, ASCL1 and NEUROD1 distinguish hetero-
geneity in SCLC with distinct genomic landscapes
and distinct gene expression programs.INTRODUCTION
Small cell lung cancer (SCLC) accounts for 10%–15% of all lung
cancers (Siegel et al., 2013). Clinically, SCLCpresents as a highly
aggressive malignant lung tumor that displays poorly differenti-
ated neuroendocrine (NE) features (Stovold et al., 2012). At the
genetic level, SCLC can harbor several different mutations, but
the majority of SCLC tumors have undergone deletion or inacti-
vation of the TP53 and RB1 genes (Peifer et al., 2012). Moreover,
it is common to find transcription factors (TFs) to be genetically
amplified, including at least one member of the MYC family
(MYC, MYCN, or MYCL1) and, at times, nuclear factor I B-typeCell R
This is an open access article under the CC BY-N(NFIB) (Dooley et al., 2011; Kim et al., 2006; McFadden et al.,
2014) and SOX2 (Rudin et al., 2012). SCLC classified histologi-
cally is a heterogeneous group of cancers based on gene
expression and selective tropism for subsets of SCLC cell lines
by the Seneca Valley virus (George et al., 2015; Poirier et al.,
2013, 2015). One criterion for delineating subgroups with
different expression profiles is by differential expression of the
basic helix-loop-helix (bHLH) TFs ASCL1 and NEUROD1.
Molecular studies using human SCLC (hSCLC) cell lines show
that ASCL1 and NEUROD1 are necessary for the survival of the
cells where they are present, and they are required for tumor-
initiating capacity in xenograft assays (Jiang et al., 2009; Osada
et al., 2005; Osborne et al., 2013). NEUROD1 is also important for
migratory capabilities of NEUROD1High hSCLC cells (Osborne
et al., 2013). Even though genetic alterations of ASCL1 and
NEUROD1 have not been reported, epigenetic analysis of
hSCLC cells shows that their loci are in active chromatin regions
and are encompassedwithin super-enhancers in their respective
cell lines (Christensen et al., 2014). In addition, ASCL1 is suffi-
cient to activate NE markers in an adenocarcinoma cell line
(Osada et al., 2008), and ASCL1 with SV40 large T antigen in
lung club cells generated aggressive adenocarcinoma with NE
phenotype (Linnoila et al., 2000). Similarly, overexpression of
NEUROD1 in non-endocrine lung cancer cell lines is sufficient
to increase cell proliferation and activate an NE program
(Neptune et al., 2008).
SCLC is thought to originate from pulmonary NE cells (PNECs)
(Park et al., 2011; Sutherland et al., 2011). During normal devel-
opment, ASCL1 is critical for the proper development of several
neuronal and NE populations, including PNECs in the lung. In
mice null for Ascl1, there is a complete loss of PNECs (Borges
et al., 1997; Ito et al., 2000). Thus, ASCL1 plays a critical role in
both the normal development of mouse PNECs and the survival
of hSCLC cell lines. In mice null for Neurod1, PNECs are still pre-
sent but they are enriched in clusters (neuroepithelial bodies
[NEBs]), while the number of solitary cells is decreased (Neptuneeports 16, 1259–1272, August 2, 2016 ª 2016 The Author(s). 1259
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
et al., 2008). The relationship between ASCL1 and NEUROD1, if
any, in this NE lineage is not known, but these factors have a
temporal relationship in some neuronal lineages, such as in adult
neurogenesis in the hippocampal dendate gyrus and develop-
ment of the olfactory epithelium (Cau et al., 1997; Kim et al.,
2011). Although ASCL1 and NEUROD1 are both capable of
increasing cell proliferation while activating NE genes, it is un-
clear whether these two bHLH factors are lineally related in the
PNEC, where they bind in the genome, what genes they regulate,
and if these related factors share a common function in SCLC.
To better understand the role of the bHLH factors in SCLC, we
define ASCL1 and NEUROD1 gene targets in pulmonary NE
tumors by probing the chromatin landscape occupied by these
TFs in SCLC. Although ASCL1 and NEUROD1 are related
bHLH factors and bind a similar DNA coremotif, the vastmajority
of ASCL1- and NEUROD1-bound sites does not overlap, contain
a distinct recognition motif, and are enriched for motifs for
distinct families of TFs. The genes defined as direct downstream
targets of ASCL1 and NEUROD1 are largely non-overlapping,
and they show how these two bHLH factors differentially regu-
late key oncogenes in SCLC. Transcriptional targets of ASCL1
found in both mouse and human cancer models highlight
ASCL1’s role in regulating NOTCH signaling. Importantly, we
demonstrate that the current mouse models for SCLC reflect
ASCL1High high-grade NE tumors and that ASCL1, but not
NEUROD1, is required for tumor formation.We discuss the impli-
cations of the substantial differences in gene expression and
chromatin landscapes in the ASCL1- versus NEUROD1-defined
hSCLC cell lines, and we highlight the importance of these dis-
tinctions when assessing therapeutic outcomes in preclinical
models.
RESULTS
ASCL1 and NEUROD1 Reveal SCLC with Distinct Gene
Expression Profiles
For decades, human-derived SCLC cell lines have been used
as model systems to uncover the genetic and molecular char-
acteristics that drive malignant behavior of the tumor cells, yet
there is variation in gene expression and genetic alterations in
these lines (Dooley et al., 2011; Johnson et al., 1996; Kim
et al., 2006) (Figures 1A–1D). There are two subtypes of
SCLC cell lines, classical and variant, distinguished by histol-
ogy, MYC amplification, and lack of expression of a subset of
NE markers, such as Dopa decarboxylase (DDC) and Gastrin-
releasing peptide (GRP) (Carney et al., 1985; Gazdar et al.,
1985). Microarray analysis of 38 of these hSCLC cell lines
distinguishes multiple subgroups and reveals differential
expression of the TFs ASCL1 and NEUROD1 (Figure 1A; Table
S1). Notably, cells with a high level of ASCL1 and low level
of NEUROD1 (ASCL1High) show stronger expression of classical
NE markers DDC and GRP compared to cells that express high
levels of NEUROD1 and lower levels of ASCL1 (NEUROD1High)
(Figures 1A and 1B). In contrast, the neural genes Brain Crea-
tine Kinase (CKB) and Enolase 2 (ENO2) are expressed in all
SCLC lines (Figure 1A).
RNA sequencing (RNA-seq) from NCI-H889, NCI-H2107,
NCI-H82, and NCI-H524 confirmed that ASCL1 and NEUROD11260 Cell Reports 16, 1259–1272, August 2, 2016have contrasting expression levels in these cells (Figure 1C;
Table S2). Furthermore, whereas a majority of these cells are
mutant for TP53 and/or RB1, ASCL1High SCLC cell lines have
classic SCLC morphology and often have MYCL1 amplification,
while NEUROD1High cell lines have variant features and areMYC
amplified (Figure 1D) (Carney et al., 1985; Gazdar et al., 1985).
We used hSCLC cell line microarray data to generate ASCL1High
and NEUROD1High gene signatures. Using these signatures,
81 human primary SCLC tumor samples profiled by RNA-
seq (George et al., 2015) were clustered into ASCL1High and
NEUROD1High subgroups, as well as those expressing low or
high levels of both (Figure 1E; Table S3), confirming that the
cell line expression heterogeneity is reflected in primary tumor
data, although the primary tumors have more complexity.
ASCL1High levels are much higher than NEUROD1High in the pri-
mary tumor samples (ASCL1 fragment per kilobase per million
mapped reads [FPKM] range from 0.1 to 976 with a median of
198; NEUROD1 FPKM range from 0 to 179 with a median of 4).
Taken together, ASCL1 and NEUROD1 are differentially ex-
pressed across hSCLC cell lines and across primary tumor
samples that represent heterogeneous cell populations, with a
majority of the samples being ASCL1High.
ASCL1 and NEUROD1 Occupy Largely Distinct
Chromosomal Locations and Track with
Super-Enhancers Defined by H3K27Ac
ASCL1 and NEUROD1 activate transcription through similar
motifs. Given that ASCL1 and NEUROD1 are required in the
SCLC lines in which they are expressed (Jiang et al., 2009;
Osborne et al., 2013), we hypothesized that they may share tar-
gets required for tumor cell maintenance. To gain insight into
this possibility, we performed chromatin immunoprecipitation
sequencing (ChIP-seq) in hSCLC cell lines that express high
levels of ASCL1 (NCI-H889, NCI-H2107, and NCI-H128) or
NEUROD1 (NCI-H82 and NCI-H524) (Figure S1; Table S4). We
identified 6,250 ASCL1-bound sites (shared in NCI-H889,
NCI-H2107, and NCI-H128) and 4,193 NEUROD1-bound sites
(shared in NCI-H82 and NCI-H524) (Figure 2A). Of these,
only 304 sites were bound by both ASCL1 and NEUROD1.
These common sites are significantly more frequent (p value <
53 10300) than expected by random chance (less than ten sites
calculated for random chance), demonstrating that ASCL1 and
NEUROD1 associate with a small but significant shared set of
genes (some expressed highly in SCLC, such as INSM1,
NCAM1, and HES6) in addition to the much larger set of distinct
genes (Table S4).
The epigenetic landscape in different cell types has shown
that large domains of H3K27Ac-marked chromatin, called su-
per-enhancers, are associated with genes important in regu-
lating cell identity (Whyte et al., 2013) and, in cancer cells, at
key oncogenic genes (Hnisz et al., 2013). It was reported
recently that ASCL1, but not NEUROD1, is associated with a
super-enhancer in multiple ASCL1High hSCLC cell lines, while
in NEUROD1High cells, NEUROD1 is associated with a super-
enhancer (Christensen et al., 2014). Using H3K27Ac ChIP-seq
data for NCI-H128 and NCI-H82 (GEO: GSE36354 and
GSE62412), we identified super-enhancers and found only
5%–10% of these overlap (Figures 2B and 2C; Table S5).
Figure 1. ASCL1 and NEUROD1 Define
Heterogeneity in hSCLC
(A) Microarray expression for ASCL1, NEUROD1,
and NE genes in hSCLC cell lines that define
ASCL1High and NEURODHigh subtypes is shown
(see Table S1).
(B) Pearson correlation analysis with respect to
ASCL1 or NEUROD1 expression in hSCLC cell
lines is shown.
(C) RNA-seq shows ASCL1 and NEUROD1 in
hSCLC cell lines (see Table S2).
(D) Known mutations in cell lines used in this study
are shown.
(E) Heatmap and dendrograms using ASCL1High
and NEUROD1High gene signatures from hSCLC
cell lines stratify human primary tumors by gene
expression (see Table S3). Dendrogram on top
reflects clustering of the primary tumors, and
dendrogram on left reflects the ASCL1High and
NEUROD1High gene signatures. Blue shading
indicates NEUROD1 related, red shading indicates
ASCL1 related, and black identifies genes ex-
pressed in both subtypes of hSCLC.INSM1, a commonly expressed gene across multiple NE cell
types and in SCLC (Fujino et al., 2015; Pedersen et al., 2006),
was among the few genes associated with super-enhancers
in both cell lines. Notably, in addition to ASCL1, NCI-H128
super-enhancers associated with oncogenic genes for SCLC,
including MYCL1, NFIB, and BCL2, and lineage-specific genes
for lung, including NKX2-1, FOXA1, and FOXA2 (Figure 2B). In
contrast, NCI-H82 had super-enhancers associated with
NEUROD1 and the oncogenic gene MYC, but not the other
lineage-specific genes for lung (Figure 2B).Cell ReAs stated above, only 5%–10% of the
super-enhancers were overlapping be-
tween the hSCLC cell lines NCI-H128
and NCI-H82 (Figure 2C). To determine
how this level of overlap compares to
the overlap of super-enhancers seen in
lineage-related cells, we compared su-
per-enhancers identified in multiple
tissues by Hnisz et al. (2013) (Table S6).
We found that a 5%–10% overlap is in
the range of that seen between cells
with no related lineal history, such as brain
and hematopoietic cells (10%–20%) or
brain and mammillary epithelial cells
(14%–22%) (see Table S6 for more com-
parisons). In contrast, cells from a shared
lineage, such as hematopoietic stems
cells, T cells, and B cells, have a much
higher overlap of super-enhancers
(40%–86%) (Table S6). Thus, differential
super-enhancer locations in ASCL1High
versus NEUROD1High SCLC cell lines
support a fundamental difference in the
genomic landscape and, possibly, adistinct lineal history of the cell types comprising these hSCLC
models.
Since ASCL1 andNEUROD1 are transcriptional activators and
bind sites that reside in active regulatory regions, we asked if
these two factors are enriched in super-enhancer regions. We
found ASCL1- and NEUROD1-bound sites are enriched in su-
per-enhancer regions over that seen in regular enhancers (as
defined by H3K27Ac enrichment) (Figure 2D). In NCI-H128
(ASCL1High), 81% of the super-enhancers contained at least
one ASCL1-bound site; and in NCI-H82 (NEUROD1High), 79%ports 16, 1259–1272, August 2, 2016 1261
Figure 2. ASCL1 and NEUROD1 Binding Are Largely Non-overlapping in hSCLC Cell Line Genomes
(A) ChIP-seq signal for ASCL1 (common to NCI-H889, NCI-H2107, and NCI-H128), NEUROD1 (common to NCI-H524 and NCI-H82), and H3K27Ac at these sites
(see Table S4). Signals were quantified ±5 kb around the peak summits.
(B) Stitched H3K27Ac enhancers plotted in increasing rank order based on ChIP-seq signal minus the input signal. Super-enhancers (SEs) are labeled in blue.
(C) Venn diagram compares NCI-H128 and NCI-H82 SE overlap (see Tables S5 and S6).
(D) Bar plot shows the number of NCI-H128 H3K27Ac-defined SEs or enhancers (Enhs) with at least one ASCL1-binding site and NCI-H82 SEs or Enhs with at
least one NEUROD1-binding site.
(E) DNA motifs found in ASCL1- or NEUROD1-bound regions are shown (HOMER).
(F) Plots show the distribution of motifs ±500 bp in ASCL1 and NEUROD1 unique binding sites and shared sites.
(G) DNA motifs found in H3K27Ac-bound regions in NCI-H128 and NCI-H82. Also see Figure S1.contained at least one NEUROD1-bound site (in contrast
only 5% of regular enhancers contain ASCL1- or NEUROD1-
bound sites). Thus, within the distinct genomic landscapes of1262 Cell Reports 16, 1259–1272, August 2, 2016the ASCL1High and the NEUROD1High hSCLC, ASCL1 and
NEUROD1 occupy largely distinct sites that localize with cell
type-specific super-enhancers.
ASCL1 and NEUROD1 Bind Discrete Consensus Motifs
in SCLC
Both ASCL1 and NEUROD1 bind DNA sequences containing the
E-box motif (CANNTG) (Bertrand et al., 2002). We performed de
novo motif analysis using HOMER (Heinz et al., 2010) on the
ASCL1- and NEUROD1-binding sites in each cell line to identify
similarities or differences in their binding preferences (Figure 2E).
As expected, the primary motif returned was the E-box motif,
which was found in 92%–94% of the peak regions and enriched
at the peak center (Figures 2E and 2F). Notably, however, ASCL1
and NEUROD1 preferentially bound distinct E-box motifs. The
differences in genomic sites bound and E-box motif preference
support distinct roles for ASCL1 and NEUROD1 in SCLC cell
lines.
The differential binding of ASCL1 and NEUROD1, and the
distinct molecular profiles found in each cell line, may be a result
of cell line-specific co-factors. We searched for additional motifs
enriched in ASCL1-only and NEUROD1-only regions. In ASCL1-
only regions, motifs for NFI half sites (Roulet et al., 2002) and
Forkhead factors (Badis et al., 2009) were enriched (Figures 2E
and 2F). In contrast, NEUROD1-only regions were enriched for
the motif recognized by the homeodomain factors CRX and
OTX2. The enrichment of these motifs suggests that one or
more members of these TF families are capable of binding the
same genomic regions as ASCL1 and NEUROD1. FOXA1 and
FOXA2 from the Forkhead family and NFIB and NFIX from the
NFI family were specifically expressed in the ASCL1High hSCLC
cells (Table S2). Notably, NFIB, FOXA1, and FOXA2 also were
associated with super-enhancers in ASCL1High cells (Figure 2B).
The NEUROD1High cells specifically expressed OTX2 (Table S2),
which was associated with a super-enhancer in these cells (Fig-
ure 2B). Similar TF motifs, including the specific E-box motifs for
ASCL1 and NEUROD1, were enriched in H3K27Ac-marked re-
gions in the respective cell lines, supporting models for the
importance of a combination of these factors in regulating
transcription in SCLC (Figure 2G). These results highlight
distinct candidate co-factors that are associated with ASCL1
or NEUROD1 in the hSCLC models.
ASCL1 andNEUROD1Differentially Regulate Oncogenic
Genes in hSCLC Cell Lines
To determine candidate downstream targets of ASCL1 or
NEUROD1, we called associated genes from our ChIP-seq
data using GREAT (McLean et al., 2010) (Table S4). Among the
genes uniquely bound by ASCL1 were genes with a known func-
tion as oncogenes for SCLC, includingMYCL1, RET, SOX2, and
NFIB, and the anti-apoptotic gene BCL2. In addition, ASCL1
targets included genes important for lung development, such
as FOXA2 and NKX2-1 (Minoo et al., 1999; Zhou et al., 1997),
as well as genes characteristic of the neuroendocrine pheno-
type, including CALCA/B (encoding CGRP), NCAM1, DLL3,
and INSM1 (Figure 3A). In contrast, NEUROD1’s unique targets
included the oncogene MYC as well as genes typically associ-
ated with neuronal function, such as the TF OTX2 (Figure 3B).
To test whether predicted target genes require ASCL1 for
expression, we knocked down ASCL1 in the hSCLC cell line
NCI-H889 and assessed mRNA levels of several of the identified
targets. We show that, with an 80% knockdown of ASCL1, therewas a significant decrease in CALCA, CALCB, RET, BCL2,
MYCL1, and FOX2A, supporting the requirement for ASCL1 for
their expression in this assay (Figures 3C and 3D). Thus, in
multiple models of SCLC, we found that ASCL1 is a key regulator
of several genes known to be important for cancer growth
properties as well as lineage-specific genes for pulmonary NE
cell identity. Furthermore, ASCL1 and NEUROD1 binding is
associatedwithmostly distinct genes, highlighting their indepen-
dent requirement in hSCLC.
ASCL1 and NEUROD1 Have Largely Distinct
Transcriptional Targets
To focus the candidate downstream target list of ASCL1 or
NEUROD1, we intersected the ChIP-seq-associated genes
with a union set of genes correlated with ASCL1 or NEUROD1
expression from primary SCLC tumors and cell lines. This union
set includes genes identified as differentially expressed between
ASCL1High and NEUROD1High from the 81 primary hSCLC sam-
ples (George et al., 2015) and from the hSCLC cell lines (Table
S2). In addition, we included differentially expressed genes
from the hSCLC cell line microarray data for ASCL1High versus
NEUROD1High and ASCL1High or NEURODHigh versus the hSCLC
not expressing these TFs (Table S1).
This analysis identified 620 ASCL1 and 443 NEUROD1 candi-
date target genes (Figure S2; Table S7). Notably, there were 49
genes regulated in common including INSM1. In addition, G pro-
tein and synapse-related genes, such as SYT1, RGS7, and
GRM2, were in this group (Figure 4F). Examination of ASCL1 or
NEUROD1 unique target genes by gene ontology revealed
enrichment of genes in neuronal systems in general. Particular
to ASCL1, however, were multiple potassium channel genes
and genes associated with NEB (Figure 4F; Table S7). The latter
group includes CALCA, DDC, RET, FOXA2, and NKX2-1 as
discussed above. In contrast, NEUROD1 target genes were en-
riched in axon guidance, cholinergic synapse, and cell adhesion-
related genes (Figure 4F; Table S7). These results highlight the
distinct genetic programs regulated by ASCL1 and NEUROD1.
Strikingly, as noted in the previous section, ASCL1 appears to
be directly regulating multiple oncogenes identified in SCLC,
includingMYCL1, SOX2, RET, and BCL2, suggesting a possible
mechanism for its requirement in SCLC survival.
ASCL1-Bound Regions in a Mouse Model of Pulmonary
NE Tumors Are Homologous to Those Found in Human
SCLC Cells
Mouse models for SCLC (mSCLC) express high levels of ASCL1
(Meuwissen et al., 2003; Schaffer et al., 2010) (Figure 6). We
reasoned that common gene targets of ASCL1 in both species
would provide high-value candidates for understanding the
dependence of these tumor cells on ASCL1. We used a mouse
model for SCLC that deletes Trp53, Rb1, and Rbl2 (TCKO) in
the lung epithelium upon administration of Adenoviral-CMV::Cre
intratracheally (Schaffer et al., 2010). ChIP-seq for ASCL1 in
dissected tumors from mSCLC resulted in 3,499 DNA-bound
regions (Figures S1 and S2; Table S8). Analysis of these sites
identified the same motifs as in hSCLC cell lines, including the
E-box as the primary motif with Forkhead and NFI as secondary
motifs (Figure S1). Genes associated with ASCL1-bound sites inCell Reports 16, 1259–1272, August 2, 2016 1263
Figure 3. ASCL1 Directly Regulates Known Oncogenes in hSCLC
(A and B) ChIP-seq shows ASCL1 (A) or NEUROD1 (B) binding near oncogenes and lineage-specific genes in hSCLC cell lines.
(C) The qRT-PCR of ASCL1 targets in NCI-H889 cells infected with lentivirus containing shControl or one of two shASCL1 is shown (*p < 0.05; error bar, SEM by
standard Student’s t test).
(D) Quantification of the protein decrease from western analysis of the knockdown experiment in (C) is shown.mSCLC identified 4,033 associated genes (Table S8). Focusing
on those expressed with ASCL1 in both mouse and human
SCLC tumors, we identified 140 common targets (Figure 4D;
Figure S2; Table S9). This common list retains important regula-
tors in NEB, including ASCL1, DDC, CALCA/B, FOXA2, INSM1,
and RET, and NOTCH pathway genes, including DLL3 that en-
codes the NOTCH ligand recently used in a strategy to deliver a
cytotoxic agent to SCLC cells (Saunders et al., 2015), and
LFNG, encoding anO-fucosylpeptide 3-b-N-acetylglucosaminyl-
transferase known to modify the NOTCH extracellular domain
(Figure 4). Thus, ASCL1 is using homologous DNA regions to
regulate cancer-related genes in bothmouse and humanmodels
of SCLC.1264 Cell Reports 16, 1259–1272, August 2, 2016ASCL1, but Not NEUROD1, Is Required for Tumor
Formation in a Mouse Model of High-Grade Pulmonary
NE Tumors
ASCL1 and NEUROD1 are required for growth and survival of
hSCLC cells in vitro, in colony formation assays, and in xeno-
grafts (Jiang et al., 2009; Osborne et al., 2013). To determine if
these factors are required in vivo for formation of NE tumors in
the lung, we turned to the TCKO mouse model for SCLC
(Figures 5A and 5B). In this model, large NE tumors—
both SCLC and large cell NE carcinoma (LCNEC)—arise
within 5 months (Gazdar et al., 2015) (Figures 5C and 6A–6C).
To test the role of ASCL1 and NEUROD1, we crossed in mutant
alleles of Ascl1 (Ascl1neoFlox [Pacary et al., 2011] or Ascl1GFP
Figure 4. ASCL1 and NEUROD1 Have Largely Distinct Transcriptional Targets
Candidate direct targets of ASCL1 and NEUROD1 in SCLC, identified through gene expression profiling and ChIP-seq, are shown (see Figure S2 and Table S7).
(A) Fold change expression values of ASCL1 and NEUROD1 direct targets in ASCL1High versus NEUROD1High hSCLC cell lines (x axis) and primary SCLC tumors
(y axis) are shown.
(B) Spearman correlation values of ASCL1 and NEUROD1 direct target gene expression with respect to ASCL1 (x axis) and NEUROD1 (y axis) across 81 primary
SCLC tumors are shown.
(C) Fold change expression values of ASCL1 and NEUROD1 direct target genes in 27 ASCL1High versus five neutral (x axis) and six NEUROD1High versus five
neutral SCLC cell lines (y axis). Neutral SCLC are those with ASLC1Low and NEUROD1Low. ASCL1 unique targets (red), NEUROD1 unique targets (blue), and
shared targets (green) are shown.
(D) 640 ASCL1 and 443 NEUROD1 targets were identified with 49 of them shared.
(E) There are 141 ASCL1 targets conserved between mSCLC and hSCLC models (see Figure S2 and Tables S8 and S9).
(F) Examples of ASCL1, NEUROD1, and shared target genes in SCLC models highlighting TF, Notch pathway, and neuronal-related genes (see Table S7 for
details on ontology and pathway analysis). Genes highlighted in red are ASCL1 targets conserved between mSCLC and hSCLC (see Table S9).[Leung et al., 2007]) or Neurod1 (Neurod1Flox) (Goebbels et al.,
2005). Strikingly, if Ascl1 was removed (Ascl1neoFlox/neoFlox or
Ascl1neoFlox/GFP collectively called Ascl1CKO) along with the
TCKO, no NE tumors formed (Figure 5D). This was assessed
histologically by determining tumor load or tumor count22–27 weeks post-infection with Adenoviral-CMV::Cre (Figures
5F and 5G). Even animals heterozygous for Ascl1 (Ascl1CKO/+)
had a significant decrease in tumor formation. It is likely that a
requirement for ASCL1 in maintenance/survival of pulmonary
NE cells, whether they are Rb/TP53 mutant or not, contributesCell Reports 16, 1259–1272, August 2, 2016 1265
Figure 5. ASCL1, but Not NEUROD1, Is Required for Tumor Formation in a Mouse Model of High-Grade Pulmonary NE Tumors
(A) Alleles used for the mSCLC model referred to as the triple knockout, TCKO, after Cre recombination. CKO alleles of Ascl1 and Neurod1 also are shown.
(B) Timeline for tumor induction is shown.
(C–E) H&E histology of lung sections from TCKO (C), TCKO;Ascl1CKO (D), and TCKO;Neurod1CKO (E) mice infected intratracheally with Adenoviral-Cre 25 weeks
earlier. Note the lack of tumor when Ascl1 is absent. (C’–E’) High magnification of tissue in (C)–(E) is shown.
(F and G) Graphs show tumor load (F) and tumor count (G) in lungs from TCKOmice with Ascl1 and Neurod1 genotypes as indicated (n = 10–16 as shown; error
bars, mean ± SEM; **p < 0.01 by one-way ANOVA).
(H) PCR genotype forNeurod1 verifying tumors are mutant forNeurod1. Deleted allele is 600 bp, Flox allele is 850 bp, and wild-type is 750 bp. Also see Figure S3.to the lack of tumor formation detected in this paradigm, since
we found 60% fewer NEBs and solitary PNECs in Ascl1f/f;
RosaLSLtdTOM relative to controlsRosaLSLtdTOM after intratracheal
infection with Adeno-CMV::CRE (Figure S3). Nevertheless, these
results highlight the requirement for ASCL1 for NE tumor forma-
tion in the lung in vivo.
In contrast to the dramatic absence of tumor formation in the
SCLCmousemodel in the absence ofAscl1, loss ofNeurod1 had
no effect. When Neurod1Flox/Flox (Neurod1CKO) was included in
the TCKO model, tumor load and tumor count were indistin-
guishable from animals in the presence of Neurod1 (Figures
5E–5G). Efficient deletion of Neurod1 in the tumors was verified
by PCR (Figure 5H). In addition, tumors continued to express
high levels of NE markers, such as CGRP, synaptophysin1266 Cell Reports 16, 1259–1272, August 2, 2016(SYP), and ASCL1. Thus, ASCL1, but not NEUROD1, is required
for tumor formation in this mouse model of high-grade NE
cancer.
NEUROD1 Is Not Detected in Mouse Pulmonary NE
Lineages and mSCLC Represents ASCL1High-type, Not
NEUROD1High-type, Tumors
The NE tumors formed in the TCKO co-express high levels of
ASCL1 and the characteristic NE markers SYP and CGRP (Fig-
ures 6A–6E). No NEUROD1 was detected in these tumors either
by protein or RNA assay. Immunocytochemistry on CGRP+ tu-
mors with antibodies against NEUROD1 detected no protein
(Figures 6F–6F’’) even when NEUROD1 was detected in other
tissues, such as olfactory epithelium (Figure 6G). In addition,
Figure 6. ASCL1, but Not NEUROD1, in Normal Lung NE Cells and in mSCLC
(A–C) Adjacent lung sections from a TCKOmouse infected intratracheally with Adenoviral-CMV::Cre 25weeks earlier. NE tumors are evident by H&E histology (A),
expression of ASCL1 (B), and SYP (C). (A’–C’) High magnification of tissue in (A)–(C) is shown.
(D–F’’) Immunofluorescence shows tumor cells identified by SYP (blue) or CGRP (blue) that co-express ASCL1 (red), but not NEUROD1 (red).
(G) Immunofluorescence shows NEUROD1 in olfactory epithelium as a positive control for the antibody.
(H) Western blots show ASCL1, but not NEUROD1, in mSCLC.
(I) RNA-seq genomic tracks show expression of Ascl1, Syp, and Calca, but not Neurod1, in mSCLC.
(J) P40 Neurod1::Cre;RosaLSLtdTom mouse lung showing Neurod1-lineage cells (TOM+) are detected in neurons (TUJ1+), but not NE cells (CGRP+), in NEBs.
(K) TOM+ cells are detected in the cerebellum (Cb), a known Neurod1-lineage.
(L) Quantification of the number of Neurod1-lineage (TOM+) cells detected in NE cells in lungs of P0 and P40 mice is shown.
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western blots did not detect NEUROD1 in the mSCLC although
ASCL1 was present (Figure 6H). Finally, RNA-seq from mSCLC
tumor tissue showed high expression of Ascl1, Syp, and Calca,
but no Neurod1 (Figure 6I). These results demonstrate that the
current models of mSCLC reflect the ASCL1High-type, but not
the NEUROD1High-type, of SCLC.
The lack of NEUROD1 in the mSCLC tumors prompted us to
revisit expression of NEUROD1 in normal lung, particularly in
PNECs in neonates and adult mice. We first performed immuno-
cytochemistry for NEUROD1 in post-natal day (P)0 and P40
mouse lung. Although we could detect NEUROD1 in neuronal
tissues like olfactory epithelium, cerebellum, and hippocampus,
we could not definitively detect NEUROD1+ cells in lung tissue
(data not shown). Because these are negative data and we as-
sessed only two post-natal stages, we turned to a Neurod1::Cre
mouse (Li et al., 2014) to label cells that have expressedNeurod1
at any time during development. Using a RosaLSLtdTOM Cre re-
porter line (Ai14), we examined Neurod1-lineage cells in P0
and P40 lung. We detected Neurod1-lineage cells (TOM+) in
the lung, but they always co-labeled with the neuronal marker
TUJ1, not the PNEC marker CGRP (Figures 6J–6J’’’), consistent
with PNECs receiving neuronal input (Van Lommel, 2001) and
NEUROD1 expression in developing sensory neurons (Ma
et al., 1996). As a positive control, we also showedNeurod1-line-
age cells in the granule neurons in the cerebellum at P0 (Fig-
ure 6K). Examination of 276 NEBs and 244 solitary PNECs in
these lungs revealed no Neurod1-lineage cells in the NE
compartment (Figure 6L). Use of a second Neurod1::Cremouse
line and a Neurod1::GFP mouse line from the GENSAT project
(Gong et al., 2003) also detected no Neurod1-lineage cells in
NE cells in lung (data not shown). From this analysis, we
conclude that NEUROD1 is not normally present in mouse
pulmonary NE lineages, although Neurod1-lineage neurons
innervate NEBs.
DISCUSSION
ASCL1 and NEUROD1 are required for cell survival in multiple
human-derived SCLC cell lines in which they are expressed
(Jiang et al., 2009; Osborne et al., 2013). In experiments to un-
cover transcriptional targets for ASCL1 and NEUROD1 and to
test their requirement in vivo, we reveal that (1) these factors
stratify the hSCLC cell lines into those likely derived from the
typical ASCL1-defined lung NE cell lineage versus those that
have a distinctly different chromatin landscape and are of
unknown origin; (2) these bHLH factors regulate largely distinct
targets; (3) ASCL1 directly regulates known SCLC oncogenes;
and (4) ASCL1, but not NEUROD1, is required in vivo for tumor
formation in a genetically engineeredmousemodel of pulmonary
NE tumors.
ASCL1 and NEUROD1 Identify hSCLC Cell Lines that
Have Distinct Chromatin Landscapes and Gene
Expression Programs: Do They Also Have Distinct
Cellular Origins?
For decades, biological and preclinical studies of SCLC have
largely depended on the availability of human tumor cell
lines (Gazdar et al., 2010). There is an acknowledged hetero-1268 Cell Reports 16, 1259–1272, August 2, 2016geneity in these cells given that they can harbor different ge-
netic alterations, display distinct epigenetic profiles, have
variant morphologies, can vary in expression of NE markers,
and have distinct vulnerabilities to viral infection (Carney
et al., 1985; Gazdar et al., 1985; Poirier et al., 2013, 2015).
ASCL1 and NEUROD1 levels in these cell lines stratify them
into subtypes (Figure 1) (Poirier et al., 2013, 2015). Recent
RNA-seq data from primary SCLC tumors (George et al.,
2015) support the prevalence of high ASCL1 across samples,
the presence of NEUROD1 in a subset of tumors, and a gene
signature for the ASCL1High and NEUROD1High subtypes
derived from the cell lines that stratify these primary SCLC
samples (Figure 1).
Multiple lines of evidence illustrate that the ASCL1High and
NEUROD1High SCLC lines have distinct chromatin land-
scapes. First, super-enhancers identified by H3K27Ac have
characteristic genomic locations that can be used to infer
broad lineage relationships (Hnisz et al., 2013). Notably, the
super-enhancers in the two subtypes of hSCLC are in largely
distinct locations (Figure 2) (Christensen et al., 2014),
and the low percentage of super-enhancers common bet-
ween the subtypes is in the range seen between lineally
unrelated cells (Hnisz et al., 2013) (Table S6). Furthermore,
de novo motif analysis performed either from ASCL1- and
NEUROD1-bound regions or enhancers defined by H3K27Ac
identifies motifs for distinct TFs. Differences in chromatin
landscapes and TF motifs found in H3K27Ac-enriched regions
have been used to distinguish cell-lineage relationships
across tissues (Heinz et al., 2010; Stergachis et al., 2013).
Together, these findings highlight multiple differences at the
chromatin level between the ASCL1High and NEUROD1High
subgroups of hSCLC.
The striking differences seen between the ASCL1High and
NEUROD1High subgroups of hSCLC, combinedwith the absence
of Neurod1 in mouse lung NE cells and in the mSCLC, suggest
the possibility that the heterogeneity arises from different cell
types of origin. The ASCL1High subgroup almost certainly arises
from mutations originating in the resident ASCL1+ NEBs in the
lung. However, the origin of the NEUROD1High tumor cells is
not clear. It is possible that NEUROD1High hSCLC originates
from a rare NEUROD1+ NE cell type that is more prevalent in hu-
man versus mouse lung that has not yet been identified. It is also
possible that it originates from NE cells from extrapulmonary
sites and hasmetastasized to the lung. Finally, the NEUROD1High
hSCLC may represent a cancer cell type not present in normal
tissue but represent an NEB lineage cell substantially altered at
the chromatin level from the ASCL1-defined NEB. Uncovering
the origin of the NEUROD1-expressing cells will be important
in understanding the heterogeneity seen in hSCLC.
It is important to note that studies of SCLC using the hSCLC
cell lines to model the biology of SCLC often use the ASCL1High
and NEUROD1High cell lines interchangeably. Indeed, many
studies preferentially use the NEUROD1High cells, such as
NCI-H82, that represent the minority of hSCLC. This practice
may cause confusion in the interpretation of results, and future
studies should consider the differences in the hSCLC cell line
subtypes when designing and interpreting results from these
experiments.
Distinct DNA-Binding Profiles of ASCL1 and NEUROD1
in SCLC Reveal Motif Preferences and Identify Potential
Collaborating Factors
De novo identification ofmotifs in ASCL1- andNEUROD1-bound
regions revealed distinct co-factor motifs, implicating specific
families of TFs that may collaborate with the bHLH factors in tu-
mor formation and/or maintenance. Forkhead and NFI motifs
were found enriched within the ASCL1-bound regions (Figure 2).
Of the four NFI factors, NFIB is often overexpressed and genet-
ically amplified in SCLC, and it has been shown to regulate cell
viability and proliferation during tumor formation (Dooley et al.,
2011). In addition, NFIB is associated with a super-enhancer in
the ASCL1High SCLC line (Figure 2). There are dozens of Fork-
head family members that could work through the Forkhead
motif identified in ASCL1-bound sites, and several of these fac-
tors have been shown to be mis-regulated and important for
several types of cancers (Myatt and Lam, 2007). FOXO3 has
overlapping sites with ASCL1 in neural progenitor cells (Webb
et al., 2013). However, FOXO3 and other FOXO factor mRNA
are present only at low levels in the hSCLC and mSCLC models.
In contrast, FOXA1 and FOXA2 are highly expressed in the SCLC
tumors in human and mouse (Tables S7 and S9), and they are
associated with super-enhancers in the ASCL1High SCLC cells,
highlighting them as candidates for a role with ASCL1 in SCLC.
In addition, ASCL1 is bound near the FOXA2 gene and FOXA2
is decreased when ASCL1 is knocked down in hSCLC (Figure 3).
In future studies, FOXA1 and FOXA2, along with ASCL1 and
NFIB, should be assessed for a role in regulating genes impor-
tant for the survival of SCLC.
In contrast, NEUROD1-bound regions are enriched for a
motif recognized by the homeodomain factor OTX2. OTX2 is
specifically expressed in some NEUROD1High SCLC cells and
NEUROD1 appears to directly regulate OTX2 (Figure 3). OTX2
is required for cell proliferation in pre-clinical models of medullo-
blastoma (Bunt et al., 2012). Consistent with this function in
SCLC, we found NEUROD1 sites containing the OTX2 motif
associated with the oncogene MYC. Lastly, OTX2 is identified
near a super-enhancer in NEUROD1High SCLC cells (Christensen
et al., 2014; Figure 2). Thus, OTX2 may collaborate with
NEUROD1 in maintaining cell proliferation in NEUROD1High tu-
mors. Altogether, ChIP-seq has implicated TFs that may work
with ASCL1 and NEUROD1 for survival of the tumor cells in
which they are expressed.
ASCL1 and NEUROD1 Regulate Oncogenic Genes and
Neural-Associated Genes
NE lung tumors in both mice and humans have a tendency to
harbor several somatic mutations, such as genetic amplifica-
tions ofMYCL1,NFIB, and SOX2 (Dooley et al., 2011; McFadden
et al., 2014; Rudin et al., 2012). ASCL1 binds near these loci
suggesting it directly regulates the expression of these key onco-
genes. Other ASCL1 targets, such as RET and DLL3, are impor-
tant for SCLC. RET is an oncogene in SCLC (Dabir et al., 2014;
Jiang et al., 2009), and, recently, an antibody-drug conjugate tar-
geted to DLL3 blocked survival of pulmonary NE tumor-initiating
cells in patient-derived xenograft models of SCLC (Saunders
et al., 2015). It is notable that, even in SCLC, ASCL1 regulates
NOTCH signaling components such as DLL3 and LNFG origi-nally identified in neural development (Figure 4) (Castro et al.,
2006; Henke et al., 2009). In addition, BCL2 appears to be
strongly expressed and required for several ASCL1High human
pulmonary NE tumors, and treatment of mice carrying ASCL1High
SCLC or NE-NSCLC xenografts with a BCL2 inhibitor showed in-
hibition of tumor growth (Augustyn et al., 2014; Tse et al., 2008).
Thus, although there are no reported genetic alterations in the
ASCL1 loci in SCLC, ASCL1 is a transcriptional activator directly
targeting known oncogenes for SCLC. A loss of ASCL1 as a
driver of these oncogenic factors may partially explain the
requirement for ASCL1 in tumor survival.
ASCL1 Is Required for Pulmonary NE Tumor Formation
In Vivo
The ASCL1High subtype of SCLC represents a majority of SCLC
based on multiple lines of evidence. First, most hSCLC cell lines
and primary tumor samples are ASCL1High (Figure 1) (George
et al., 2015). Second, ASCL1 is normally present in lung NE cells
during development and in the adult, and it is essential for this
lineage to develop (Ito et al., 2000). In addition, ASCL1 is highly
expressed in the pulmonary NE tumors in the mouse model,
and it is essential for these tumors to form (Figure 5). Thus,
ASCL1 is a lineage-specific oncogene for SCLC. On the other
hand, although NEUROD1 expression was reported in neonatal
lung tissue in mice (Neptune et al., 2008) and loss of NEUROD1
disrupts the pattern of NEBs formed, NEUROD1 itself is not pre-
sent in the mouse lung NE cells. Rather, neurons that innervate
the NEBs and whose cell bodies are expected to be in sensory
ganglia outside of the lung are from the Neurod1 lineage.
Furthermore, mSCLC tumor tissue does not have detectable
NEUROD1mRNA, and Neurod1 is not required for tumor forma-
tion or maintenance in the mouse model (Figures 5 and 6). Thus,
unlike adult neurogenesis where ASCL1 and NEUROD1 are
present in the same lineage at different stages as progenitors
transition to neurons, in the lung, ASCL1 and NEUROD1 do not
appear to be lineally related.
The Trp53, Rb1, and Rbl2 triple-knockout mouse model most
closely relates to the ASCL1High hSCLC subtype, and it reveals a
possible progression from LCNEC to SCLC over time (Gazdar
et al., 2015; Schaffer et al., 2010). Both LCNEC and SCLC ex-
press high levels of ASCL1, and both tumor types require
ASCL1 for formation, since in the mSCLC model lacking Ascl1
no NE tumors form. Unexpectedly, even the loss of one allele
of Ascl1 dramatically reduces tumor load and incidence. This
may have therapeutic implications as a partial inhibition of
ASCL1 may substantially attenuate tumor growth in humans,
and it indicates the need for focusing therapeutic targeting of
the ASCL1 pathway.
EXPERIMENTAL PROCEDURES
Detailed information may be found in the Supplemental Experimental
Procedures.
Mouse Strains and Tumor Induction
The SCLC mouse model with conditional deletions in Trp53 (p53), Rb1, and
Rbl2 (p130) was described previously (Schaffer et al., 2010). The Ascl1neoFlox
(Pacary et al., 2011),Ascl1GFP (Ascl1tm1Reed/J) (Leung et al., 2007),Neurod1Flox
(Goebbels et al., 2005), and Neurod1::Cre (Li et al., 2014) mice were describedCell Reports 16, 1259–1272, August 2, 2016 1269
previously. Adenovirus expressing CMV::Cre (University of Iowa Viral Vector
Core) was administered intratracheally to 6-week-old mice (males and fe-
males) at 2.5 3 107 plaque-forming units (PFUs) as described (DuPage
et al., 2009). Lungs from all infected mice were harvested between 22 and
27 weeks post-infection. All procedures on animals followed NIH Guidelines
and were approved by the University of Texas (UT) Southwestern Institutional
Animal Care and Use Committee.
Tissue Processing and Immunohistochemistry
Lungs were inflated then submerged for 1 hr using 4% paraformaldehyde,
rinsed, paraffin embedded, sectioned at 10 mm, and random sections were
processed for H&E and then imaged on a digital slide scanner (Nanozoomer
XR-12000). Antibodies used include the following: guinea pig anti-ASCL1
(1:5,000, J.E.J. lab generated TX518) (Kim et al., 2008), rabbit anti-SYP
(1:500, Pierce PA5-27286), rabbit anti-CGRP (1:500, Sigma C8198), mouse
anti-TUJ1 (1:1,000, BioLegend 801201), and goat anti-NEUROD1 (1:500,
Santa Cruz Biotechnology N-19).
Cell Culture and ASCL1 Knockdown and Western Blots
Cell lines used were from the Hamon Cancer Center Collection (UT South-
western Medical Center), maintained in RPMI-1640 (Life Technologies)
supplemented with 5%–10% fetal bovine serum (FBS). The lentiviral small
hairpin RNA (shRNA) vector pTY-shRNA-EF1a-puroR-2a-GFP was used.
The shRNA sequences are as follows: shASCL1(1), 50-GCAGCACACGCGTT
ATAGTTT-30; 50-ACTATAACGCGTGTGCTGCTC-30 and shASCL1(2): 50-CAA
CTGCAATTTTCCCTATTT-30; 50-ATAGGGAAAATTGCAGTTGTA-30. Primers
for qPCR for specific genes are included in the Supplemental Experimental
Procedures. Antibodies for western blotting were guinea pig anti-ASCL1
(1:1,000, J.E.J. lab generated TX518) (Kim et al., 2008) and rabbit anti-
NEUROD1 (1:1,000, Abcam ab109224).
RNA-Seq, ChIP-Seq, and Microarray
Tumors from lungs of Trp53;Rb1;Rbl2 triple-knockout mice were pooled from
an individual mouse and RNA or chromatin extracted. For hSCLC cell lines, 107
cells were used. ThemSCLC sequencing library preparation used Illumina Tru-
Seq and single-end 50-bp sequencing on the Illumina Hi-Seq 2000. The
hSCLC cell line libraries weremade using the SOLiD Fragment Library Barcod-
ing Kit (Applied Biosystems) and sequenced (50-bp reads) on an ABI SOLiD.
RNA-Seq data are available (GEO: GSE69398). Mouse mm9 and human
hg19 genome assemblies were used for sequence alignment. Microarray
data were generated for gene expression in human tumor cell lines (GEO:
GSE32036). RNA-seq from primary SCLC tumors was from George et al.
(2015).
For ChIP-seq, 250 mg mouse tumor or 100 mg human cell line chromatin was
immunoprecipitated with 5 mg mouse anti-ASCL1 antibody (BD Biosciences,
556604) or with 5 mg goat anti-NEUROD1 (Santa Cruz Biotechnology, N-19).
ChIP-seq libraries were sequenced on an Illumina High-Seq 2000 or Illumina
GAIIx (GEO: GSE69398). Sequence reads for each sample were mapped to
the hg19 or mm9 genome assemblies as relevant with Bowtie (Trapnell
et al., 2009). Duplicate reads were removed, and the remaining unique reads
were normalized to ten million reads. Peak calling was performed by HOMER
(Heinz et al., 2010) using a false discovery rate (FDR) cutoff of 0.001, a cumu-
lative Poisson p value of < 0.0001, and a required 4-fold enrichment of normal-
ized sequenced reads in the treatment sample over the control/input sample.
Normalized sequence reads around each peak were counted in 25-bp bins
and loaded into MATLAB to generate heatmaps.
Motif discovery was conducted with HOMER package v4.2. In ChIP-seq
data we used the following settings: –size 150 –S 10 –bits (Heinz et al.,
2010). We limited the motif analysis to a 150-bp DNA region around each
peak summit. In H3K27AC-enriched regions, we used –size given as the
parameter as these regions are broad. Distance to gene and gene annotations
for ChIP-seq peaks were obtained using GREAT v1.82 (McLean et al., 2010).
Super-enhancers were determined using H3K27Ac ChIP-seq data from (Lin
et al., 2012) (GEO:GSE36354) and (Christensen et al., 2014) (GEO:GSE62412),
calculated by HOMER using bound regions that were significant at Poisson
p value threshold of 13 109 for the super-enhancer prediction. Rank ordering
of super-enhancers was by ROSE (Love´n et al., 2013; Whyte et al., 2013).1270 Cell Reports 16, 1259–1272, August 2, 2016Pathway enrichment analysis was performed using ConsensusPathDB
tool (Kamburov et al., 2011) to identify overrepresented gene sets. Significantly
enriched pathways (FDR% 5%) were selected (Figure 4; Tables S7 and S9).
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